DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
MN-166 is an investigational drug.
There have been 11 clinical trials for MN-166. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2019.
The most common disease conditions in clinical trials are Sclerosis, Motor Neuron Disease, and Amyotrophic Lateral Sclerosis. The leading clinical trial sponsors are MediciNova, University of California, Los Angeles, and National Institute on Alcohol Abuse and Alcoholism (NIAAA).
There are eight hundred and four US patents protecting this investigational drug and seven international patents.
Recent Clinical Trials for MN-166
|Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS||MediciNova||Phase 2|
|Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS||MediciNova||Phase 2/Phase 3|
|Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers||MediciNova||Phase 1|
Top disease conditions for MN-166
Top clinical trial sponsors for MN-166
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|MN-166||Get Started Free||Heterocyclic compound||Takeda Pharmaceutical Company Limited (Osaka, JP)||Get Started Free|
|MN-166||Get Started Free||Therapeutic approaches for treating Parkinson's disease||Pharnext (Issy les Moulineaux, FR)||Get Started Free|
|MN-166||Get Started Free||Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells||Selecta Biosciences, Inc. (Watertown, MA)||Get Started Free|
|MN-166||Get Started Free||Method of purifying authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag||The Catholic University of America (Washington, DC)||Get Started Free|
|MN-166||Get Started Free||Ultra-pure agonists of guanylate cyclase C, method of making and using same||SYNERGY PHARMACEUTICALS, INC. (New York, NY)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|MN-166||Canada||CA2961033||2034-09-11||Get Started Free|
|MN-166||European Patent Office||EP3192791||2034-09-11||Get Started Free|
|MN-166||Japan||JPWO2016039408||2034-09-11||Get Started Free|
|MN-166||World Intellectual Property Organization (WIPO)||WO2016039408||2034-09-11||Get Started Free|
|MN-166||Australia||AU2012222348||2031-03-01||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|